Clarithromycin destroys biofilms and enhances bactericidal agents in the treatment of Pseudomonas aeruginosa osteomyelitis

Clinical Orthopaedics and Related Research

Volumn 430, Issue , 2005, Pages 171-175

  Kandemir, Özlem ^a,c   Öztuna, Volkan ^a   Milcan, Abtullah ^a   Bayramoǧlu, Alp ^b   Çelik, H Hamdi ^b   Bayarslan, Cemil ^a   Kaya, Ali ^a  

^a MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c MERSIN UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDE; CEFTAZIDIME; CLARITHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BIOFILM; BONE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; ELECTRON MICROSCOPY; FOREIGN BODY; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; TIBIA; TREATMENT OUTCOME;

EID: 11844255624     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000137551.45447.89     Document Type: Article

References (27)

1. Baron EJ. Peterson LR, Finegold SM: Diagnostic Microbiology. Baltimore, Mosby 284-295, 1994.
2. Bui KQ, Banevicius MA, Nightingale CH, Quintiliani R, Nicolau DP: In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa. J Antimicrob Chemother 45:57-62, 2000.
3. Chuard C, Lucet JC, Rohner P, et al: Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J Infect Dis 163:1369-1373, 1991.
4. Cremieux AC, Carbon C: Experimental models of bone and prosthetic joint infections. Clin Infect Dis 25:1295-1302, 1997.
5. Dickinson GM, Bisno AL: Infections associated with indwelling devices: Concepts of pathogenesis: Infections associated with intravascular devices. Antimicrob Agents Chemother 33:597-601, 1989.
6. Evans DJ, Alison DG, Brown MR, Gilbert P: Susceptibility of Pseudomonas aeruginosa and Escherichia coli biofilms toward ciprofloxacin: Effect of specific growth rate. J Antimicrob Chemother 27:177-184, 1991.
7. Gill VJ, Fedorko DP, Witebsky FG: The Clinician and the Microbiology Laboratory. In Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases. Ed 5. Vol 1. Philadelphia, Churchill Livingstone 184-221, 2000.
8. Gristina AG, Hobgood CD, Webb LX, Myrvik QN: Adhesive colonization of biomaterials and antibiotic resistance. Biomaterials 8:423-426, 1987.
9. Harkess JW: Arthroplasty of Hip. In Canale T (ed). Campbell's Operative Orthopaedics. Vol 1. St Louis, Mosby 296 297, 1998.
10. Hienz SA, Sakamoto H, Flock JI, et al: Development and characterization of a new model of hematogenous osteomyelitis in the rat. J Infect Dis 171:1230-1236, 1995.
11. Howe RA, Spencer RC: Macrolides for treatment of Pseudomonas aeruginosa infections? J Antimicrob Chemother 40:153-155, 1997.
12. Ichimiya T, Yamasaki T, Nasu M: In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. J Antimicrob Chemother 34:331-341, 1994.
13. Johnson GM, Lee DA, Regelmann WE, et al: Interference with granulocyte function by Staphylococcus epidermidis slime. Infect Immun 54:13-20, 1986.
14. Kondoh K, Hashiba M, Baba S: Inhibitory activity of clarithromycin on biofilm synthesis with Pseudomonas aeruginosa. Acta Otolaryngol 525(Suppl):56-60, 1996.
15. Littlewood-Evans AJ, Hattenberger M, Zak O, O'Reilly T: Effect of combination therapy of rifampicin and azithromycin on TNF levels during a rat model of chronic osteomyelitis. J Antimicrob Chemother 39:493-498, 1997.
16. Mai GT, McComarck JG, Seow WK, et al: Inhibition of adherence of mucoid Pseudomonas aeruginosa by alginase, specific monoclonal antibodies, and antibiotics. Infect Immun 61:4338-4343, 1993.
17. Marrie TJ, Costerton JW: Mode of growth of bacterial pathogens in chronic polymicrobial human osteomyelitis. J Clin Microbiol 22:924-933, 1985.
18. Neu HC: Synergy of fluoroquinolones with antimicrobial agents. Rev Infect Dis 11:1025-1035, 1989.
19. Nichols WW, Evans MJ, Slack MPE, Walmsley HL: The penetration of antibiotics into aggregates of mucoid and non-mucoid Pseudomonas aeruginosa. J Gen Microbiol 185:1291-1303, 1989.
20. Nicolau DP, Banevicius MA, Nightingale CH, Quintiliani R: Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model. Antimicrob Agents Chemother 43:3033-3035, 1999.
21. Nicolls MR, Weiss SM, Schwarz MI: Recognition and treatment of diffuse panbronchiolitis. Infect Med 15:657-662, 1998.
22. Ozeki M, Miyamoto N, Hashiba M, Baba S: Inhibitory effect of roxithromycin on biofilm formation of Pseudomonas aeruginosa. Acta Otolaryngol 525(Suppl):61-63, 1996.
23. Tanimoto H: A review of the recent progress in treatment of patients with diffuse panbronchiolitis associated with Pseudomonas aeruginosa infection in Japan. Antibiot Chemother 44(Suppl):94-98, 1991.
24. Vaudaux PE, Zulian G, Huggler E, Waldvogel FA: Attachment of Staphylococcus aureus to polymethyl-methacrylate increases its resistance to phagocytosis in foreign body infection. Infect Immun 50:472-477, 1985.
25. Virolainen P, Lahteenmaki H, Hiltunen A, et al: The reliability of diagnosis of infection during revision arthroplasties. Scand J Surg 91:178-181, 2002.
26. Widmer AF, Wiestner A, Frei R, Zimmerli W: Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother 35:741-746, 1991.
27. Yasuda H, Ajiki Y, Koga T, Kawada H, Yokota T: Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrob Agents Chemother 37:1749-1755, 1993.